Clinical Trial

Upadacitinib for Refractory Takayasu Arteritis

Name: Upadacitinib for Refractory Takayasu Arteritis — clinical trial record (NCT07500467)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches.Upadacitinib is an oral, selective JAK1 inhibitor that potently inhibits JAK1 activity, representing a potential therapeutic option.This study aims to assess the efficacy and safety of upadacitinib in refractory Takayasu arteritis.

Trial Details

NCT Number	NCT07500467
Lead Sponsor	Liu Tian
Conditions	Takayasu Arteritis
Enrollment	12 participants
Start Date	2024-03-19
Primary Completion	2026-01-31 (estimated)
Study Completion	2026-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-30